SiBone $SIBN Shares Sold by Granahan Investment Management LLC

Key Points

• Granahan Investment Management LLC has decreased its stake in SiBone by 12.3%, now holding approximately 1,432,701 shares and accounting for 1.0% of its holdings.
• Several institutional investors, including ANTIPODES PARTNERS Ltd and Johnson Investment Counsel, have recently acquired new positions in SiBone, reflecting significant investor interest as institutional ownership reaches 98.11%.
• Wall Street analysts have varied opinions on SiBone, with ratings ranging from a downgrade to "hold" by Wall Street Zen and a target price of $25.00 set by Cantor Fitzgerald.

Granahan Investment Management LLC lessened its position in SiBone (NASDAQ:SIBN - Free Report) by 12.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,432,701 shares of the company's stock after selling 201,865 shares during the quarter. SiBone accounts for 1.0% of Granahan Investment Management LLC's portfolio, making the stock its 27th largest position. Granahan Investment Management LLC owned about 3.36% of SiBone worth $20,101,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. American Century Companies Inc. lifted its holdings in SiBone by 11.1% during the 1st quarter. American Century Companies Inc. now owns 2,642,322 shares of the company's stock valued at $37,072,000 after buying an additional 264,254 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of SiBone by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 2,444,159 shares of the company's stock valued at $34,292,000 after purchasing an additional 35,349 shares in the last quarter. Silvercrest Asset Management Group LLC raised its holdings in shares of SiBone by 21.9% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock valued at $27,392,000 after purchasing an additional 350,970 shares in the last quarter. First Light Asset Management LLC raised its holdings in shares of SiBone by 41.8% in the 1st quarter. First Light Asset Management LLC now owns 1,612,408 shares of the company's stock valued at $22,622,000 after purchasing an additional 475,426 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY raised its holdings in shares of SiBone by 5.3% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company's stock valued at $19,432,000 after purchasing an additional 69,831 shares in the last quarter. Institutional investors own 98.11% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on SIBN shares. Wall Street Zen lowered shares of SiBone from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the company an "overweight" rating in a report on Monday, August 11th. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $23.67.

SiBone Stock Down 0.4%

Shares of SiBone stock traded down $0.06 on Friday, reaching $16.29. The stock had a trading volume of 240,114 shares, compared to its average volume of 320,173. The company has a 50 day moving average price of $16.88 and a 200 day moving average price of $16.48. The company has a quick ratio of 7.00, a current ratio of 8.38 and a debt-to-equity ratio of 0.21. SiBone has a 1 year low of $11.70 and a 1 year high of $20.05. The stock has a market capitalization of $702.75 million, a P/E ratio of -29.09 and a beta of 0.81.

SiBone (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. The company had revenue of $48.63 million for the quarter, compared to the consensus estimate of $48.12 million. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. SiBone has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that SiBone will post -0.78 EPS for the current year.

Insider Buying and Selling at SiBone

In related news, CEO Laura Francis sold 11,343 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $15.60, for a total transaction of $176,950.80. Following the sale, the chief executive officer directly owned 419,704 shares of the company's stock, valued at approximately $6,547,382.40. This represents a 2.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Anshul Maheshwari sold 3,461 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $15.57, for a total transaction of $53,887.77. Following the transaction, the chief financial officer directly owned 214,445 shares in the company, valued at approximately $3,338,908.65. The trade was a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,590 shares of company stock worth $765,137. Corporate insiders own 3.90% of the company's stock.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.